NEW YORK, Feb. 15, 2016 /PRNewswire/ -- The recent discovery of liquid biopsy technology and its wide applicability have sparked off a lot of interest among researchers along with the commercial players. Owing to the same, there are numerous clinical trials being organized all over the world in order to assess the potential of liquid biopsy in various fields such as cancer, prenatal screening and organ transplant monitoring.
As indicated by the new estimation carried out in our most recent study, the global liquid biopsy industry is expected to cross US$ 1 Billion mark by the end of 2020, as new products, especially those in the advanced stage of clinical studies or with pending approvals, might enter the market to support the development.
According to RNCOS' new research report "Global Liquid Biopsy Market Outlook to 2020", a major focus has been on the development of innovative products based on different technologies and different sample types. In this context, the study provides present and future outlooks for the two broad categories of liquid biopsy market; by technology and by sample type. The former comprises of the three marker categories that dominate liquid biopsy today: Circulating Tumor Cells (CTCs), circulating tumor DNA (ctDNA), and extracellular vesicles (or exosomes). On the other hand, the latter includes the two major bodily fluid samples: blood and urine. According to report, blood is the most widely used sample type, and is expected to remain the largest market based on sample type in the coming years as well. The report also includes a detailed pipeline analysis of upcoming liquid biopsy products along with the sample type utilized.
Most of the current research is focused on utilizing liquid biopsy for diagnostic purposes, such as response evaluation, expression profiling, tumor diagnosis and treatment monitoring in a blood test. The flexible design of the liquid biopsy platform supports a variety of research areas, including Stem cell research, Oncology, Infectious Disease, Immunology, Endothelial Cells, and Fetal Cells.
The market has been divided into four major geographic regions - North America, Europe, Asia and Rest of the World. North America is the largest market for the liquid biopsy. This high share is attributed to relative high adoption of liquid biopsy, coupled with launch of new and advanced products in the market. The Asian market is poised to witness the highest growth owing to increasing focus of players in this region.
RNCOS, in its report, further covers how major trends and drivers, mainly therapy monitoring, increasing use of Circulating tumor DNA for cancer screening, growing interest of venture capital firms, etc. will propel the industry's growth. An analysis has also been done of a few factors limiting the growth of the industry.
After an exhaustive study of the industry, RNCOS has laid out the primary market players which are engaged in providing liquid biopsy based tools and services. These players are working over a vast variety of products, such as blood based tests, urine based tests, assays and instruments for sample extraction, amplification and purification, and constantly upgrading their portfolio to keep up with the latest developments in the field. Some of these players include NeoGenomics, Trovagene, Guardant Health, Biocept, Biocartis, and Pathway Genomics.
Overall, even though the market is in its nascent stage at the moment, it is expanding at an almost exponential rate. With new players entering the market, increase in the number of collaborations and strong support from research institutes, the liquid biopsy market is bound to witness rampant diversification and growth in the coming years.
Read the full report: http://www.reportlinker.com/p03621491-summary/view-report.html
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.